Drugs /

pictilisib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
pictilisib
NCI Definition [1]:
A small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Clinical Trials

View Clinical Trials for pictilisib

Pictilisib has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating pictilisib, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).

HER2 Deficient Expression, HER2 Negative, and AR Negative are the most frequent biomarker inclusion criteria for pictilisib clinical trials.

Breast carcinoma and malignant solid tumor are the most common diseases being investigated in pictilisib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pictilisib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pictilisib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pictilisib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gdc-0941
Drug Categories [2]:
PI3K inhibitors, Tyrosine kinase inhibitors
Drug Target(s) [2]:
PIK3CA, PIK3CB, PIK3CD, PIK3CG

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.